KBW Maintains Outperform on Genworth Financial, Cuts Target to $11.5

0 min read | Published on 16 Sept 2026, 11:41 PM |Updated on 16 Sept 2026, 11:41 PM

Reviewed by

Ritika DScanX News Team

Add as a preferred
source on Google

Key Highlights

Keefe, Bruyette & Woods maintains Outperform rating on Genworth Financial
Price target lowered from $12 to $11.5 by analyst Ryan Krueger
Genworth Financial trades on NYSE under ticker GNW

*this image is generated using AI for illustrative purposes only.

Keefe, Bruyette & Woods analyst Ryan Krueger maintained an Outperform rating on Genworth Financial (NYSE: GNW) while lowering the price target from $12 to $11.5.

The adjustment reflects a downward revision in the firm's valuation model for the insurance provider.

Analyst Action Details

Metric	Previous Value	New Value
Rating	Outperform	Outperform
Price Target	$12	$11.5

Krueger’s decision to retain the bullish stance despite the lower target suggests the underlying business thesis remains intact, albeit at a reduced valuation multiple.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific changes in Genworth's valuation model or macroeconomic assumptions drove the 4% reduction in the price target?

How might this slight downgrade in valuation multiple impact investor sentiment given that the 'Outperform' rating was maintained?

Are there upcoming regulatory developments or capital requirement changes in the insurance sector that could further pressure Genworth's near-term profitability?

Genworth Financial authorizes extra $500 million for share repurchases

1 min read | Published on 03 Sept 2026, 01:56 AM |Updated on 03 Sept 2026, 02:05 AM

Reviewed by

Naman SScanX News Team

Add as a preferred
source on Google

Key Highlights

Genworth Financial authorizes an additional $500 million for share repurchases
Prior $350M program saw 30 million shares bought for $262 million as of Sept 1, 2026
CEO cites Enact’s higher capital returns in 2026 as supporting future cash flows
Funding will come from holding company cash and Enact dividends, excluding AXA litigation proceeds

*this image is generated using AI for illustrative purposes only.

Genworth Financial, Inc. (NYSE: GNW) announced its Board of Directors has authorized an additional $500 million for the repurchase of common stock shares.

The expansion reinforces the company’s capital return strategy. As of September 1, 2026, approximately 30 million shares had been acquired at an aggregate cost of $262 million under the prior $350 million authorization, leaving roughly $88 million remaining.

Capital Return Strategy

CEO Tom McInerney stated the move reflects confidence in Genworth’s financial position and ability to return capital. He noted that Enact Holdings, Inc.’s plans for higher capital returns in 2026 strengthen expected cash flows.

Repurchases will be funded from current holding company cash and future cash flows from Enact. The company clarified that these plans do not incorporate potential proceeds from AXA litigation.

Program Details

Metric	Value
New Authorization	$500 million
Prior Authorization	$350 million
Shares Repurchased (Prior)	30 million
Cost of Prior Repurchases	$262 million
Remaining (Prior Auth)	$88 million

Purchases may occur via open market transactions, private negotiations, or Rule 10b5-1 plans. The authorization has no expiration date and may be modified or terminated at any time.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might the timing and pace of Genworth's $500 million share repurchases be influenced by the outcome of the ongoing AXA litigation?

What specific metrics will Genworth use to balance its increased capital return strategy with its long-term obligations as a life insurance provider?

How could Enact Holdings' projected higher capital returns in 2026 impact Genworth's liquidity and ability to sustain this new repurchase authorization?